Sprint Bioscience
1.87 SEK
-2.86 %
Less than 1K followers
SPRINT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Sprint Bioscience
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 33.5 | 16.9 | 35.1 | 0.1 | 50.5 | 65.6 | 167.2 |
| growth-% | -49.7 % | 108.0 % | -99.8 % | 63,012.5 % | 30.0 % | 154.7 % | |
| EBITDA | -19.5 | -37.2 | -25.0 | -61.1 | -0.4 | -18.7 | 98.4 |
| EBIT | -20.2 | -37.8 | -25.6 | -60.7 | -0.9 | -19.7 | 97.3 |
| Profit before taxes | -21.5 | -42.8 | -25.1 | -60.2 | -0.4 | -18.3 | 91.7 |
| Net income | -21.5 | -42.8 | -25.1 | -60.2 | -0.4 | -18.3 | 91.7 |
| EPS | -1.41 | -2.03 | -0.71 | -1.41 | -0.01 | -0.26 | 0.99 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | 0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -58.2 % | -220.0 % | -71.3 % | -76,400.0 % | -0.8 % | -28.5 % | 58.8 % |
| EBIT-% | -60.3 % | -224.2 % | -73.0 % | -75,925.0 % | -1.7 % | -30.0 % | 58.2 % |
| ROE | -195.5 % | -468.0 % | -35.6 % | -213.4 % | -2.1 % | -197.2 % | 77.0 % |
| ROI | -111.9 % | -128.1 % | -31.7 % | -160.8 % | -0.7 % | -43.5 % | 67.1 % |